[go: up one dir, main page]

EA200700338A1 - Ингибиторы рнк-зависимой рнк-полимеразы вируса гепатита с и композиции и способы лечения с их использованием - Google Patents

Ингибиторы рнк-зависимой рнк-полимеразы вируса гепатита с и композиции и способы лечения с их использованием

Info

Publication number
EA200700338A1
EA200700338A1 EA200700338A EA200700338A EA200700338A1 EA 200700338 A1 EA200700338 A1 EA 200700338A1 EA 200700338 A EA200700338 A EA 200700338A EA 200700338 A EA200700338 A EA 200700338A EA 200700338 A1 EA200700338 A1 EA 200700338A1
Authority
EA
Eurasian Patent Office
Prior art keywords
inhibitors
methods
compositions
treatment
rna
Prior art date
Application number
EA200700338A
Other languages
English (en)
Other versions
EA012605B1 (ru
Inventor
Хавьер Гонсалес
Таня Мишель Джуэлл
Гуи Ли
Анджелика Линтон
Джон Хоуард Тэтлок
Original Assignee
Пфайзер Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Пфайзер Инк. filed Critical Пфайзер Инк.
Publication of EA200700338A1 publication Critical patent/EA200700338A1/ru
Publication of EA012605B1 publication Critical patent/EA012605B1/ru

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D309/00Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
    • C07D309/32Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/335Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/351Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom not condensed with another ring
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D513/00Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Pyrane Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Согласно настоящему изобретению предложены соединения формулы (4) и их фармацевтически приемлемые соли и сольваты, которые полезны в качестве ингибиторов фермента полимеразы вируса гепатита С (HCV), а также полезны для лечения HCV-инфекций у HCV-инфицированных млекопитающих. Согласно настоящему изобретению также предложены фармацевтические композиции, содержащие соединения формулы (4), их фармацевтически приемлемые соли и сольваты. Кроме того, согласно настоящему изобретению предложены промежуточные соединения и способы, полезные в получении соединений формулы (4).
EA200700338A 2004-08-18 2005-08-05 Ингибиторы рнк-зависимой рнк-полимеразы вируса гепатита с и композиции и способы лечения с их использованием EA012605B1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US60261804P 2004-08-18 2004-08-18
PCT/IB2005/002697 WO2006018725A1 (en) 2004-08-18 2005-08-05 Inhibitors of hepatitis c virus rna-dependent rna polymerase, and compositions and treatments using the same

Publications (2)

Publication Number Publication Date
EA200700338A1 true EA200700338A1 (ru) 2007-08-31
EA012605B1 EA012605B1 (ru) 2009-10-30

Family

ID=35429645

Family Applications (1)

Application Number Title Priority Date Filing Date
EA200700338A EA012605B1 (ru) 2004-08-18 2005-08-05 Ингибиторы рнк-зависимой рнк-полимеразы вируса гепатита с и композиции и способы лечения с их использованием

Country Status (42)

Country Link
US (3) US7151105B2 (ru)
EP (1) EP1781662B1 (ru)
JP (1) JP4372195B2 (ru)
KR (1) KR100851178B1 (ru)
CN (2) CN101006092B (ru)
AP (1) AP2313A (ru)
AR (1) AR050699A1 (ru)
AT (1) ATE506364T1 (ru)
AU (1) AU2005273619B2 (ru)
BR (1) BRPI0514425A (ru)
CA (1) CA2577525C (ru)
CR (2) CR8935A (ru)
CY (1) CY1111480T1 (ru)
DE (1) DE602005027580D1 (ru)
DK (1) DK1781662T3 (ru)
EA (1) EA012605B1 (ru)
EC (1) ECSP077264A (ru)
ES (1) ES2361845T3 (ru)
GE (2) GEP20115305B (ru)
GT (1) GT200500221A (ru)
HN (1) HN2005000449A (ru)
HR (1) HRP20110458T1 (ru)
IL (2) IL180933A (ru)
MA (1) MA28803B1 (ru)
MX (1) MX2007001527A (ru)
MY (1) MY146123A (ru)
NI (1) NI200700043A (ru)
NL (1) NL1029755C2 (ru)
NO (1) NO20071274L (ru)
NZ (1) NZ552874A (ru)
PE (1) PE20060677A1 (ru)
PL (1) PL1781662T3 (ru)
PT (1) PT1781662E (ru)
RS (1) RS51794B (ru)
SI (1) SI1781662T1 (ru)
SV (1) SV2007002202A (ru)
TN (1) TNSN07066A1 (ru)
TW (1) TWI376379B (ru)
UA (1) UA88909C2 (ru)
UY (1) UY29068A1 (ru)
WO (1) WO2006018725A1 (ru)
ZA (1) ZA200700779B (ru)

Families Citing this family (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4372195B2 (ja) * 2004-08-18 2009-11-25 ファイザー・インク C型肝炎ウイルスrna依存性rnaポリメラーゼの阻害剤、並びにそれを使用する組成物及び治療
BRPI0615016A2 (pt) 2005-08-24 2011-05-03 Pfizer compostos inibidores de hcv polimerase, métodos para prepará-los e forma cristalina
CN102872461A (zh) 2007-05-04 2013-01-16 弗特克斯药品有限公司 用于治疗hcv感染的组合治疗
EP2008996A1 (en) * 2007-06-27 2008-12-31 Syngeta Participations AG Process for the production of pyrazoles
CN102083852A (zh) 2008-06-06 2011-06-01 西尼克斯公司 环孢菌素类似物及其在治疗hcv感染中的应用
CN104530048B (zh) 2008-08-11 2016-09-14 葛兰素史密丝克莱恩有限责任公司 腺嘌呤衍生物
JP2011530562A (ja) 2008-08-11 2011-12-22 グラクソスミスクライン エルエルシー アレルギー性、炎症性及び感染性疾患治療用のプリン誘導体
UA103195C2 (ru) 2008-08-11 2013-09-25 Глаксосмитклайн Ллк Производные пурина для применения в лечении аллергий, воспалительных и инфекционных заболеваний
UY32940A (es) 2009-10-27 2011-05-31 Bayer Cropscience Ag Amidas sustituidas con halogenoalquilo como insecticidas y acaricidas
BR112012010110A2 (pt) 2009-10-30 2019-09-24 Boehringer Ingelheim Int regimes de dosagem para terapia combinada para hcv compreendendo bi201335, interferon alfa e ribavirina
EP2325173A1 (de) 2009-11-19 2011-05-25 Bayer CropScience AG Verfahren zum Herstellen von 5-Fluor-1-alkyl-3-fluoralkyl-1H-pyrazol-4-carbonsäurechloriden
PH12012501216A1 (en) * 2009-12-18 2012-11-05 Boehringer Ingelheim Int Hcv combination therapy
JP2013519644A (ja) 2010-02-10 2013-05-30 グラクソスミスクライン エルエルシー プリン誘導体およびそれらの薬学的使用
CA2786973C (en) 2010-02-10 2018-04-10 Robert Hermann Gibbon 6-amino-2-{[(1s)-1-methylbutyl] oxy}-9-[5-(1-piperidinyl)-7,9-dihydro-8h-purin-8-one maleate
CN102906073B (zh) 2010-05-20 2015-11-25 拜耳知识产权有限责任公司 1-烷基-3-二氟甲基-5-羟基吡唑的制备方法
US8987307B2 (en) 2011-03-03 2015-03-24 Hoffmann-La Roche Inc. 3-amino-pyridines as GPBAR1 agonists
FR2972452B1 (fr) * 2011-03-09 2013-03-15 Rhodia Operations Procede de preparation du difluoroacetonitrile et de ses derives
WO2013171134A1 (de) 2012-05-14 2013-11-21 Bayer Cropscience Ag Verfahren zum herstellen von 1-alkyl-3-fluoralkyl-1h-pyrazol-4-carbonsäurechloriden
WO2014081878A2 (en) 2012-11-21 2014-05-30 Stategics, Inc. Substituted triazolo-pyrimidine compounds for modulating cell proliferation, differentiation and survival
MX361768B (es) 2013-01-17 2018-12-17 Bayer Cropscience Ag Proceso para preparar 5-fluoro-1-metil-3-difluorometil-1h-pirazol- 4-carbaldehido.
EA028858B9 (ru) 2013-02-06 2018-06-29 Байер Кропсайенс Акциенгезельшафт Галогензамещенные производные пиразола в качестве средств борьбы с вредителями
RU2016131792A (ru) 2014-01-03 2018-02-06 Байер Энимэл Хельс ГмбХ Новые пиразолил-гетероариламиды в качестве средств для борьбы с вредителями
BR112016016397B1 (pt) 2014-01-24 2021-06-29 Bayer Cropscience Aktiengesellschaft Processo para preparar 1-alquil-3-difluorometil-5- fluoro-1h-pirazol-4-carbaldeídos ou os seus ésteres
CN106029668B (zh) 2014-02-20 2018-02-23 葛兰素史克知识产权第二有限公司 吡咯并[3,2]嘧啶衍生物作为人类干扰素诱导剂
MA40281B1 (fr) 2014-06-03 2018-11-30 Idorsia Pharmaceuticals Ltd Composés de pyrazole et leur utilisation en tant qu' agents de blocage des canaux calciques de type t
MX2017006302A (es) 2014-11-13 2018-02-16 Glaxosmithkline Biologicals Sa Derivados de adenina que son utiles en el tratamiento de enfermedades alergicas u otras afecciones inflamatorias.
WO2017093180A1 (de) 2015-12-01 2017-06-08 Bayer Cropscience Aktiengesellschaft Kondensierte bicyclische heterocyclen-derivate als schädlingsbekämpfungsmittel
CR20180286A (es) 2015-12-03 2018-07-16 Glaxosmithkline Ip Dev Ltd Dinucleotidos de purina cíclicos como moduladores de sting
SI3440076T1 (sl) 2016-04-07 2022-09-30 Glaxosmithkline Intellectual Property Development Limited Heterociklični amidi uporabni kot proteinski modulatorji
BR112018070602A2 (pt) 2016-04-07 2019-02-05 Glaxosmithkline Ip Dev Ltd composto, composição farmacêutica, uso do composto, e, método para tratar uma doença ou distúrbio
MX2019001918A (es) 2016-08-15 2019-09-06 Bayer Cropscience Ag Derivados del heterociclo biciclico condensado como agentes de control de plagas.
EP3301094A1 (en) * 2016-09-30 2018-04-04 Mutabilis Heterocyclic compounds and their use in preventing or treating bacterial infections
EP3554490B1 (en) 2016-12-16 2022-02-16 Idorsia Pharmaceuticals Ltd Pharmaceutical combination comprising a t-type calcium channel blocker
EP3577099B1 (en) 2017-02-06 2024-01-24 Idorsia Pharmaceuticals Ltd A novel process for the synthesis of 1-aryl-1-trifluoromethylcyclopropanes
CN117430622B (zh) 2017-10-04 2025-12-19 拜耳公司 用作害虫防治剂的杂环化合物的衍生物
TW201927771A (zh) 2017-10-05 2019-07-16 英商葛蘭素史密斯克藍智慧財產發展有限公司 可作為蛋白質調節劑之雜環醯胺及其使用方法
JP7291130B2 (ja) 2017-10-05 2023-06-14 グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッド インターフェロン遺伝子の刺激物質(sting)の調節物質
EP3765466B1 (de) 2018-03-12 2022-05-25 Bayer Aktiengesellschaft Kondensierte bicyclische heterocyclen-derivate als schädlingsbekämpfungsmittel
WO2019201921A1 (de) 2018-04-20 2019-10-24 Bayer Aktiengesellschaft Heterocyclen-derivate als schädlingsbekämpfungsmittel
GB201807924D0 (en) 2018-05-16 2018-06-27 Ctxt Pty Ltd Compounds
EP3901147B1 (en) 2019-01-25 2023-11-22 Beijing Scitech-MQ Pharmaceuticals Limited Acylamino bridged heterocyclic compound, and composition and application thereof
JP2022533194A (ja) 2019-05-16 2022-07-21 スティングセラ インコーポレイテッド ベンゾ[b][1,8]ナフチリジン酢酸誘導体および使用方法
EP3969438A1 (en) 2019-05-16 2022-03-23 Stingthera, Inc. Oxoacridinyl acetic acid derivatives and methods of use
GB201910305D0 (en) 2019-07-18 2019-09-04 Ctxt Pty Ltd Compounds
GB201910304D0 (en) 2019-07-18 2019-09-04 Ctxt Pty Ltd Compounds
AU2020409429A1 (en) 2019-12-18 2022-06-16 Ctxt Pty Ltd Compounds
US12274700B1 (en) 2020-10-30 2025-04-15 Accencio LLC Methods of treating symptoms of coronavirus infection with RNA polymerase inhibitors
CN112194620B (zh) * 2020-12-04 2021-02-26 苏州开元民生科技股份有限公司 一种2-乙基-4-氰基吡啶的制备方法
CN113563167B (zh) * 2021-07-16 2023-09-08 南通华祥医药科技有限公司 一种2-甲基-1-四氢萘酮的制备方法

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3786063A (en) 1971-05-24 1974-01-15 Universal Oil Prod Co Thiazolethiosulfonates
DE2155360C3 (de) * 1971-11-08 1980-04-03 Cassella Ag, 6000 Frankfurt Verfahren zur Herstellung von Acylbernsteinsäuredialkylestern
CA1144937A (en) 1977-12-22 1983-04-19 Dke J.E. Helgstrand Aromatic derivatives, pharmaceutical compositions and methods for combatting virus infections
US4326058A (en) 1979-02-05 1982-04-20 Sumitomo Chemical Company, Limited Organo-phosphoric esters and their production and use
US4489077A (en) 1983-03-23 1984-12-18 Warner-Lambert Company 3-Isoxa-zolyl-2H-1,2-benzothiazine-3-carboxamide, 1,1-dioxides
US6174868B1 (en) 1992-09-10 2001-01-16 Isis Pharmaceuticals, Inc. Compositions and methods for treatment of hepatitis C virus-associated diseases
AU688344B2 (en) 1993-07-19 1998-03-12 Mitsubishi-Tokyo Pharmaceuticals, Inc. Hepatitis C virus proliferation inhibitor
ES2219457T3 (es) 1993-11-19 2004-12-01 PARKE, DAVIS & COMPANY Derivados de 5,6-dihidropironas como inhibidores de proteasa y agentes antiviricos.
US5840751A (en) 1993-11-19 1998-11-24 Warner-Lambert Company 5,6-dihydropyrone derivatives as protease inhibitors and antiviral agents
US6005103A (en) 1993-11-19 1999-12-21 Warner-Lambert Company Pyrone derivatives as protease inhibitors and antiviral agents
US5504104A (en) 1993-11-19 1996-04-02 Warner-Lambert Company Tricyclic pyrone derivatives as protease inhibitors and antiviral agents
CZ291856B6 (cs) 1993-11-19 2003-06-18 Parke, Davis & Company 5,6-Dihydropyronové deriváty jako inhibitory proteázy a protivirová činidla a farmaceutické kompozice obsahující tyto deriváty
US5834506A (en) 1996-11-01 1998-11-10 Warner-Lambert Company Dihydropyrones with improved antiviral activity
AU773567B2 (en) 1998-09-11 2004-05-27 Warner-Lambert Company HIV protease inhibitors
US6512006B1 (en) 1999-12-09 2003-01-28 Warner-Lambert Company HIV protease inhibitors
EP1256628A3 (en) 2001-05-10 2003-03-19 Agouron Pharmaceuticals, Inc. Hepatitis c virus (hcv) ns5b rna polymerase and mutants thereof
DOP2003000641A (es) * 2002-05-10 2003-11-15 Pfizer Inhibidores de las arn polimerasa dependiente de arn del virus de las hepatitis c y composiciones y tratamiento que los usan
US7148226B2 (en) * 2003-02-21 2006-12-12 Agouron Pharmaceuticals, Inc. Inhibitors of hepatitis C virus RNA-dependent RNA polymerase, and compositions and treatments using the same
JP4372195B2 (ja) * 2004-08-18 2009-11-25 ファイザー・インク C型肝炎ウイルスrna依存性rnaポリメラーゼの阻害剤、並びにそれを使用する組成物及び治療

Also Published As

Publication number Publication date
CN101538268B (zh) 2011-07-27
AU2005273619B2 (en) 2009-05-28
ES2361845T3 (es) 2011-06-22
NZ552874A (en) 2010-04-30
AP2313A (en) 2011-10-31
PE20060677A1 (es) 2006-08-11
MY146123A (en) 2012-06-29
PL1781662T3 (pl) 2011-08-31
UY29068A1 (es) 2006-03-31
TW200612898A (en) 2006-05-01
EP1781662B1 (en) 2011-04-20
TWI376379B (en) 2012-11-11
US20060122399A1 (en) 2006-06-08
IL180933A0 (en) 2007-07-04
IL180933A (en) 2011-08-31
CA2577525A1 (en) 2006-02-23
US7622605B2 (en) 2009-11-24
CR20110153A (es) 2011-04-26
JP2008509984A (ja) 2008-04-03
NL1029755C2 (nl) 2006-10-18
MX2007001527A (es) 2007-03-27
US20090281122A1 (en) 2009-11-12
CN101006092B (zh) 2013-04-17
EA012605B1 (ru) 2009-10-30
KR20070044057A (ko) 2007-04-26
ATE506364T1 (de) 2011-05-15
US20070015764A1 (en) 2007-01-18
ZA200700779B (en) 2008-11-26
US7151105B2 (en) 2006-12-19
DE602005027580D1 (de) 2011-06-01
EP1781662A1 (en) 2007-05-09
SV2007002202A (es) 2007-03-20
ECSP077264A (es) 2007-04-26
CY1111480T1 (el) 2015-08-05
US8268835B2 (en) 2012-09-18
CR8935A (es) 2007-07-24
GT200500221A (es) 2006-06-21
BRPI0514425A (pt) 2008-06-10
RS51794B (sr) 2011-12-31
WO2006018725A1 (en) 2006-02-23
HK1109617A1 (en) 2008-06-13
JP4372195B2 (ja) 2009-11-25
TNSN07066A1 (fr) 2008-06-02
HRP20110458T1 (hr) 2011-07-31
CN101538268A (zh) 2009-09-23
SI1781662T1 (sl) 2011-07-29
MA28803B1 (fr) 2007-08-01
UA88909C2 (ru) 2009-12-10
NI200700043A (es) 2008-01-02
CN101006092A (zh) 2007-07-25
IL192919A0 (en) 2009-02-11
AP2007003918A0 (en) 2007-02-28
HN2005000449A (es) 2009-10-30
GEP20094751B (en) 2009-08-10
DK1781662T3 (da) 2011-06-27
NO20071274L (no) 2007-05-14
GEP20115305B (en) 2011-10-10
KR100851178B1 (ko) 2008-08-08
NL1029755A1 (nl) 2006-02-21
AU2005273619A1 (en) 2006-02-23
CA2577525C (en) 2010-03-30
AR050699A1 (es) 2006-11-15
PT1781662E (pt) 2011-07-01

Similar Documents

Publication Publication Date Title
EA200700338A1 (ru) Ингибиторы рнк-зависимой рнк-полимеразы вируса гепатита с и композиции и способы лечения с их использованием
EA200802346A1 (ru) Циклопропилконденсированные индолобензазепиновые ингибиторы белка ns5b вируса гепатита с
MX2007004783A (es) Inhibidores de la proteasa del virus de la hepatitis c, y composiciones y tratamientos que los usan.
CL2004001161A1 (es) Compuestos describe compuestos derivados de quinolina; composicion farmaceutica; y su uso para tratar una enfermedad causada por el virus de la hepatitis c.
WO2004009020A3 (en) Pyrrolopyrimidine thionucleoside analogs as antivirals
WO2003105770A3 (en) Carbocyclic nucleoside analogs as rna-antivirals
EA200900298A1 (ru) Ингибиторы вируса гепатита с
JO2318B1 (en) Nucleoside derivatives used as DNA-based viral RNA inhibitors
WO2005123087A3 (en) C-purine nucleoside analogs as inhibitors of rna-dependent rna viral polymerase
ATE481106T1 (de) Heterocyclische sulfonamid-hepatitis-c-virus- hemmer
ZA200805304B (en) Anti-viral compounds
EA200500584A1 (ru) Нуклеозидные производные для лечения инфекционных заболеваний, вызванных вирусом гепатита c
WO2004007512A3 (en) Nucleoside derivatives as inhibitors of rna-dependent rna viral polymerase
WO2004000858A3 (en) Nucleoside derivatives as inhibitors of rna-dependent rna viral polymerase
WO2004003138A3 (en) Nucleoside derivatives as inhibitors of rna-dependent rna viral polymerase
WO2007021610A3 (en) Ribonucleoside cyclic acetal derivatives for the treatment of rna-dependent rna viral infection
EA201000277A1 (ru) Соединения для лечения гепатита с
ATE498398T1 (de) Cycloalkyl-heterozyklen zur behandlung des hepatitis-c-virus
EA200400690A1 (ru) Нуклеозиды, их препараты и их применение в качестве ингибиторов вирусных рнк-полимераз
TW200745107A (en) Anti-viral compounds
DOP2005000165A (es) Inhibidores de la arn polimerasa dependiente de arn del virus de la hepatitis c y composiciones y tratamientos que los usan

Legal Events

Date Code Title Description
TK4A Corrections in published eurasian patents
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ BY KZ KG MD TJ TM RU